rAAV miRNA Delivery for Osteoblast and Osteoclast Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current osteoporosis therapies suppress osteoclast-mediated bone resorption but concurrently decrease osteoblast-mediated bone formation, leading to limited therapeutic effects.
Innovation Solution
Recombinant adeno-associated viruses (rAAVs) encoding microRNAs (miRNAs) or miRNA inhibitors are used to modulate bone growth by inhibiting miR-214-3p and/or overexpressing miR-34a-5p in osteoblasts and osteoclasts, enhancing osteogenesis and/or decreasing osteoclastogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If osteoclast-mediated bone resorption is suppressed by current osteoporosis therapies, then bone loss is reduced, but osteoblast-mediated bone formation decreases concurrently, leading to limited therapeutic effects
Solution Approach 1:
The invention changes the molecular parameters by introducing specific miRNAs (miR-34a-5p, miR-214-3p) and their inhibitors to regulate gene expression at the post-transcriptional level. This parameter change in gene regulation enables selective modulation of osteoblast and osteoclast activity, resolving the contradiction by enhancing bone formation through miR-34a-5p while suppressing bone resorption through miR-214-3p inhibition, thereby improving therapeutic effect without compromising bone formation
Solution Approach 2:
The invention uses AAV vectors as intermediary delivery systems to transport miRNA and miRNA inhibitor molecules to target cells. These intermediaries enable precise delivery of therapeutic agents to osteoblasts and osteoclasts, allowing independent regulation of bone formation and resorption processes. The AAV-miRNA complex acts as a mediator that resolves the contradiction by enabling selective gene silencing in specific cell types without affecting other bone cells
2Strength
If miR-214-3p is inhibited and miR-34a-5p is overexpressed using rAAVs, then osteogenesis is enhanced and osteoclastogenesis is decreased, but the complexity of the therapy increases
Solution Approach 1:
The invention merges multiple therapeutic functions into a single rAAV vector system that can simultaneously deliver miR-34a-5p (to enhance osteogenesis) and miR-214-3p inhibitors (to suppress osteoclastogenesis). This consolidation of multiple therapeutic agents into one delivery vehicle reduces overall therapy complexity while achieving the desired dual effect of enhancing bone formation and inhibiting bone resorption
Solution Approach 2:
The rAAV vector system serves multiple functions: it acts as a delivery vehicle for miRNAs, a gene silencing mechanism for miR-214-3p, and an overexpression system for miR-34a-5p. This multi-functional approach simplifies the therapeutic regimen by using a single platform to achieve complex therapeutic goals, thereby reducing therapy complexity while improving bone density
Data Source
AI summary
Aspects of the disclosure relate to compositions and methods for modulating bone growth, for example by increasing osteogenesis and/or decreasing osteoclastogenesis. The disclosure is based, in part, on recombinant adeno-associated virus (rAAV) vectors encoding microRNAs or miRNA inhibitors that inhibit endogenous miR-214-3p and/or mediate overexpression of miR-34a-5p in osteoblasts and osteoclasts. In some embodiments, compositions described by the disclosure are useful for treating certain bone diseases or disorders, such as osteoporosis.